China Sky One Medical Wins Production Approval for Two New Drugs
Posted on: Friday, 31 October 2008, 12:00 CDT
China Sky One Medical, a provider of over-the-counter drugs, has obtained production approval from the State Food and Drug Administration in China for two of its newly developed drugs.
Sodium ferulate by injection is intended for the treatment of cardiovascular disease. It works by inhibiting the gathering of hematoblasts and stretches blood vessels in order to protect cardiac muscles.
Doxofylline by injection is intended for the treatment of asthma and bronchitis. It works on bronchia and relaxes bronchial smooth muscle in order to restrain asthma.
Yan-Qing Liu, chairman, CEO and president of China Sky One Medical, said: "We are very excited about our two new drugs and estimate that revenue from sodium ferulate will reach $1 million, and revenue from doxofylline will reach $500,000 once production starts in the beginning of 2009. We are confident that our advanced R&D capabilities will continue to help us expand our market share."
Source: Datamonitor
Related Articles
- China Drug Addicts Put at 2.3M
- FDA Mixed Up China Drug Plant Names
- Report: China Drug Ingredients Unregulated
- Shanghai Firm Investigates Banned Drug
- China Suspends Sales of Leukemia Drug
- China Halts Production of Novartis Drug
- Ex-China Drug Regulator to Be Executed
- China debates first anti-drug law
- Examine Application and Approval Procedures and Timeline for Imported Drugs in China
- Chinese Watchdog Approves Clinical Tests of Human Bird Flu Vaccine
 |
 |
User Comments (0)
RSS Feeds